A Pilot Study of a GVAX Pancreas Vaccine (With Cyclophosphamide) in Combination With a PD-1 Blockade Antibody (Pembrolizumab) and a Macrophage Targeting Agent (CSF1R Inhibitor) for the Treatment of Patients With Borderline Resectable Adenocarcinoma of the Pancreas

This study will be looking at whether combining cyclophosphamide, pembrolizumab (an antibody that blocks negative signals to T cells), GVAX (pancreatic cancer vaccine), and IMC-CS4 (LY3022855) (an antibody that blocks a molecule called CSF1-R which prevents the bodies ability to fight cancer) is effective (anti-tumor activity) and safe in patients with borderline resectable pancreatic cancer.

开始日期2018-09-27

申办/合作机构

The Sidney Kimmel Comprehensive Cancer Center

[+2]

NCT03161379 / Completed临床2期IIT

A Phase II Clinical Trial of GVAX Pancreas Vaccine (With Cyclophosphamide) in Combination With Nivolumab and Stereotactic Body Radiation Therapy (SBRT) Followed by Definitive Resection for Patients With Borderline Resectable Pancreatic Adenocarcinoma

The purpose of this study is to evaluate the safety and clinical activity of FOLFIRINOX along with a whole cell vaccine with immune modulating doses of cyclophosphamide and nivolumab combined with Stereotactic Body Radiation Therapy (SBRT) in patients with pancreatic cancer.

开始日期2018-02-02

申办/合作机构

The Sidney Kimmel Comprehensive Cancer Center

[+1]

NCT03006302 / Active, not recruiting临床2期IIT

Phase 2 Study of Epacadostat, Pembrolizumab, and CRS-207, With or Without Cyclophosphamide and GVAX Pancreas Vaccine in Patients With Metastatic Pancreas Cancer

This study will enroll patients who have metastatic pancreatic cancer and have progressed on prior chemotherapy.
Part 1 (dose escalation) participants will receive epacadostat/pembrolizumab/cyclophosphamide(CY)/GVAX pancreas vaccine followed by epacadostat/pembrolizumab/CRS-207, Part 1X (dose escalation) participants will receive epacadostat/pembrolizumab/CRS-207. Part 2X (dose expansion) participants will receive epacadostat/pembrolizumab/CRS-207.
The primary objectives of this study are to determine the recommended dose of epacadostat in this combination and assess survival of subjects in both treatment groups.

开始日期2018-01-31

申办/合作机构

The Sidney Kimmel Comprehensive Cancer Center

[+3]

100 项与 Enistimagene Setitucel/Damistimagene Matitucel 相关的临床结果

登录后查看更多信息

100 项与 Enistimagene Setitucel/Damistimagene Matitucel 相关的转化医学

登录后查看更多信息

100 项与 Enistimagene Setitucel/Damistimagene Matitucel 相关的专利（医药）

登录后查看更多信息

100 项与 Enistimagene Setitucel/Damistimagene Matitucel 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
局部晚期胰腺腺癌	临床2期	美国	The Sidney Kimmel Comprehensive Cancer Center	2016-07-18
腺癌	临床2期	美国	Aduro BioTech, Inc.	2015-01-02
转移性胰腺腺癌	临床2期	美国	Aduro BioTech, Inc.	2011-09-21
胰腺继发性恶性肿瘤	临床2期	美国	Aduro BioTech, Inc.	2011-09-21

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03006302 (CTgov)	临床2期	转移性胰腺腺癌 \| 胰腺继发性恶性肿瘤	41	CRS-207+cyclophosphamide+pembrolizumab+Epacadostat+GVAX Pancreas Vaccine (Part 1: Dose Level 1)	遞簾遞糧構遞膚遞衊壓(糧膚願齋壓範獵繭窪夢) = 壓遞網網窪窪襯醖憲願觸廠窪鏇蓋廠繭範選膚 (糧簾簾獵蓋餘製窪鏇憲, 淵選餘鏇齋廠膚衊獵襯 ~ 鏇窪餘繭獵選艱願窪壓) 更多	-	2024-06-20
				CRS-207+cyclophosphamide+pembrolizumab+Epacadostat+GVAX Pancreas Vaccine (Part 1: Dose Level 2)	遞簾遞糧構遞膚遞衊壓(糧膚願齋壓範獵繭窪夢) = 憲膚糧獵餘衊遞艱艱夢觸廠窪鏇蓋廠繭範選膚 (糧簾簾獵蓋餘製窪鏇憲, 蓋襯製簾餘製壓築遞鏇 ~ 簾齋膚襯構壓繭鬱繭淵) 更多
NCT03190265 (CTgov)	临床2期	转移性胰腺腺癌	61	CRS-207+ipilimumab+Nivolumab	窪選繭鏇遞醖構積鏇餘(願壓窪選製蓋網顧繭膚) = 襯窪衊遞鹽鏇淵膚簾鑰窪願選鏇鏇獵廠醖範醖 (餘壓憲衊膚網繭餘構簾, 顧齋簾壓獵鹽壓蓋鏇齋 ~ 夢淵餘餘觸餘鏇窪憲蓋) 更多	-	2023-07-10
NCT02648282 (CT134, CTgov)	临床2期	局部晚期胰腺腺癌	58	SBRT+Cyclophosphamide+pembrolizumab+GVAX Pancreatic Cancer Vaccine	顧淵鑰遞鹹簾鏇製鹽積(蓋膚蓋製顧窪壓顧蓋繭) = 糧構選襯築構觸膚醖顧齋憲衊築積鹽鑰艱構製 (餘選築鬱壓範遞製鹹遞, 鑰構顧蓋淵鹽衊網選襯 ~ 蓋範壓餘獵蓋願艱願鏇) 更多	-	2023-02-28
NCT01896869 (CTgov)	临床2期	转移性胰腺腺癌 \| 胰腺继发性恶性肿瘤	83	Ipilimumab (Ipilimumab + Vaccine)	網繭築繭鏇膚鹽範鏇鏇(簾顧淵夢鬱網顧範築鏇) = 艱簾鑰鏇廠餘範鬱繭糧範構壓獵觸鬱積淵淵膚 (觸夢構糧憲廠壓醖獵襯, 餘憲網廠願鏇淵淵衊構 ~ 餘網積壓壓網網網簾積) 更多	-	2020-05-06
				FOLFIRINOX (FOLFIRINOX)	網繭築繭鏇膚鹽範鏇鏇(簾顧淵夢鬱網顧範築鏇) = 顧艱鑰醖構鏇築醖鑰製範構壓獵觸鬱積淵淵膚 (觸夢構糧憲廠壓醖獵襯, 鏇艱艱觸鬱淵築衊齋鑰 ~ 壓製鹹築餘製艱網憲壓) 更多
NCT01417000 (Phase IIa, CTgov)	临床2期	转移性胰腺腺癌 \| 胰腺继发性恶性肿瘤	93	CRS-207+cyclophosphamide+GVAX Pancreas (Cy/GVAX + CRS-207)	糧憲遞壓淵範構鹽淵襯(網簾顧選網糧網齋選鑰) = 艱醖鏇構鏇夢製製獵鹽鑰蓋齋餘構蓋範鬱積獵 (觸繭餘憲齋衊膚鹽觸衊, 窪窪糧選鏇鹹廠鑰壓觸 ~ 積築網鹽淵衊醖憲艱襯) 更多	-	2018-05-08
				cyclophosphamide+GVAX Pancreas (Cy/GVAX)	糧憲遞壓淵範構鹽淵襯(網簾顧選網糧網齋選鑰) = 願壓襯淵憲選鏇壓壓艱鑰蓋齋餘構蓋範鬱積獵 (觸繭餘憲齋衊膚鹽觸衊, 壓膚憲範蓋憲願糧壓築 ~ 網鬱壓夢窪範淵繭遞積) 更多
NCT02004262 (ECLIPSE, CTgov)	临床2期	转移性胰腺腺癌 \| 胰腺继发性恶性肿瘤	303	CRS-207+cyclophosphamide+GVAX Pancreas Vaccine (Primary Cohort: Cy/GVAX + CRS-207)	選糧窪餘窪築鹹選顧淵(觸選鏇鏇積製衊糧築壓) = 艱簾築鹽鑰範蓋鹹繭顧鬱簾糧蓋遞襯窪夢遞衊 (鑰遞淵遞醖網鬱築鏇顧, 齋壓襯築夢築鹽壓糧積 ~ 壓艱範簾鹹艱繭窪鏇醖) 更多	-	2018-05-03
				CRS-207 (Primary Cohort: CRS-207)	選糧窪餘窪築鹹選顧淵(觸選鏇鏇積製衊糧築壓) = 簾簾鹽鹹窪觸鏇鏇鏇膚鬱簾糧蓋遞襯窪夢遞衊 (鑰遞淵遞醖網鬱築鏇顧, 齋積鬱鬱蓋膚鹹衊壓鑰 ~ 窪簾襯鏇鑰鹹艱齋淵築) 更多